These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9815203)

  • 1. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.
    Malley R; DeVincenzo J; Ramilo O; Dennehy PH; Meissner HC; Gruber WC; Sanchez PJ; Jafri H; Balsley J; Carlin D; Buckingham S; Vernacchio L; Ambrosino DM
    J Infect Dis; 1998 Dec; 178(6):1555-61. PubMed ID: 9815203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions.
    Malley R; Vernacchio L; Devincenzo J; Ramilo O; Dennehy PH; Meissner HC; Gruber WC; Jafri HS; Sanchez PJ; Macdonald K; Montana JB; Thompson CM; Ambrosino DM
    Pediatr Infect Dis J; 2000 Jan; 19(1):1-7. PubMed ID: 10643842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
    Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
    Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.
    Johnson S; Griego SD; Pfarr DS; Doyle ML; Woods R; Carlin D; Prince GA; Koenig S; Young JF; Dillon SB
    J Infect Dis; 1999 Jul; 180(1):35-40. PubMed ID: 10353858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome.
    Buckingham SC; Jafri HS; Bush AJ; Carubelli CM; Sheeran P; Hardy RD; Ottolini MG; Ramilo O; DeVincenzo JP
    J Infect Dis; 2002 May; 185(9):1222-8. PubMed ID: 12001038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
    Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection.
    van Woensel JB; Lutter R; Biezeveld M; Dekker T; Nijhuis M; van Aalderen WM; Kuijpers TW
    Pediatr Infect Dis J; 2003 Aug; 22(8):721-6. PubMed ID: 12913774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.
    Johnson S; Oliver C; Prince GA; Hemming VG; Pfarr DS; Wang SC; Dormitzer M; O'Grady J; Koenig S; Tamura JK; Woods R; Bansal G; Couchenour D; Tsao E; Hall WC; Young JF
    J Infect Dis; 1997 Nov; 176(5):1215-24. PubMed ID: 9359721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
    Weltzin R; Traina-Dorge V; Soike K; Zhang JY; Mack P; Soman G; Drabik G; Monath TP
    J Infect Dis; 1996 Aug; 174(2):256-61. PubMed ID: 8699052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus infection in children admitted to hospital but ventilated mechanically for other reasons.
    von Renesse A; Schildgen O; Klinkenberg D; Müller A; von Moers A; Simon A;
    J Med Virol; 2009 Jan; 81(1):160-6. PubMed ID: 19031467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab.
    Scott LJ; Lamb HM
    Drugs; 1999 Aug; 58(2):305-11; discussion 312-3. PubMed ID: 10473022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load.
    Devincenzo JP
    Pediatr Res; 2004 Dec; 56(6):914-7. PubMed ID: 15470202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG; Crowe JE; Johnson TR; Tang YW; Graham BS
    J Infect Dis; 1999 Oct; 180(4):1324-7. PubMed ID: 10479165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF; Nahata MC
    Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants.
    Buckingham SC; Bush AJ; Devincenzo JP
    Pediatr Infect Dis J; 2000 Feb; 19(2):113-7. PubMed ID: 10693996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
    Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.
    Mejías A; Chávez-Bueno S; Ríos AM; Aten MF; Raynor B; Peromingo E; Soni P; Olsen KD; Kiener PA; Gómez AM; Jafri HS; Ramilo O
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4700-7. PubMed ID: 16251314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.